herα

Anti-HER3/ERBB3 Antibody (4V862) is a Rabbit IgG monoclonal antibody targeting Human HER3/ERBB3.

Anti-HER3/ERBB3 Antibody (1P393) is a Mouse IgG1 monoclonal antibody targeting Human HER3/ERBB3.

Anti-HER3/ERBB3 Antibody (2W239) is a mouse (varialbe region) / human (kappa / IgG1 constant) chimeric monoclonal antibody targeting Human HER3/ERBB3.

Anti-HER3/ERBB3 Antibody (2Y512) is a mouse (varialbe region) / human (kappa / IgG1 constant) chimeric monoclonal antibody targeting Human HER3/ERBB3.

ABP-102 (CT P72) is a tetravalent IgG1-[L]-scFv bispecific t-cell adduct (BiTE) that acts as a CD3 modulator and selective HER2 modulator for the selective targeting of HER2 overexpressing tumors. ABP-102 showed cytotoxicity in HER2-overexpressing models of breast and gastric cancers, while significantly decreasing activity against HER2 low level cells, twice as effective as rununmotamab.

Margetuximab (MGAH-22) is a second generation anti-human epidermal growth factor receptor 2 protein (HER2) monoclonal antibody with anti-tumor activity for the study of metastatic HER2-positive breast cancer and for the synthesis of nanomedicines.

Seribantumab (MM 121) is a humanized monoclonal antibody targeting HER3, inhibiting NRG1-induced growth in MCF-7 cells and patient-derived breast and lung cancer cells harboring NRG1 fusions or amplifications. It also induces apoptosis in MDA-MB-175-VII and LUAD-0061AS3 cells.

Patritumab (U3-1287) is an anti-HER3 monoclonal antibody with potential antitumor activity and inhibits phosphorylation of EGFR, HER2, HER3, ERK, and AKT.Patritumab promotes apoptosis and inhibits proliferation in non-small cell lung cancer.

Zanidatamab (ZW25) is a humanised bispecific monoclonal antibody that simultaneously targets two distinct HER2 epitopes located on ECD2 and ECD4, thereby enhancing receptor clustering and signaling blockade, Zanidatamab exhibits strong anti-tumour activity, supporting its application in HER2-positive cancer research and antibody-based therapeutic development.

Zenocutuzumab (MCLA-128) is a humanized antibody targeting the extracellular domains of HER2 and HER3. It can be used for research on tumors driven by NRG1 gene rearrangement.

Trastuzumab beta (ABP 980), a biosimilar to Trastuzumab, is a monoclonal antibody (McAb) that targets the human epidermal growth factor receptor 2 (HER2). It is utilized in the research of HER2-positive metastatic breast cancer, early breast cancer (EBC), and metastatic gastric cancer [1].

Fidasimtamab is a recombinant human IgG1 bispecific antibody designed to target and inhibit both HER2 and PD-1 signaling pathways. Fidasimtamab bridges PD-1 expressing T cells with HER2 expressing tumor cells, thereby modulating immune responses while exhibiting potential immunosuppressive and antitumor effects. This mechanism provides an unique therapeutic approach for cancer research.

Gancotamab (MM-302) is a HER2-targeting polyethylene glycolated liposome that encapsulates adriamycin to facilitate delivery to HER2-overexpressing tumor cells while limiting exposure to non-target tissues, including the heart.Gancotamab has antitumor activity and may be used to study advanced HER2-positive breast cancer.

Izalontamab (SI-B001) is a bispecific EGFR/HER3 monoclonal antibody that binds to both EGFR×EGFR homodimers and EGFR×HER3 heterodimers, thereby blocking downstream pathways. It is applicable for locally advanced or metastatic epithelial tumours, such as non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC).

Elgemtumab (LJM716) is a fully humanised monoclonal antibody targeting HER3/ERBB3, acting as an antagonist to block HER3/Akt phosphorylation and exhibiting antitumour activity.

Inetetamab is a humanized monoclonal antibody targeting HER2 receptor domain IV, exhibiting antitumor activity through inducing pyroptosis in lung adenocarcinoma. It is used in studies of HER2-positive metastatic breast cancer.

Patritumab-MMAE , an Anti-ERBB3/HER3 Reference Antibody, is produced in CHO cells. This antibody comprises a heavy chain of type huIgG1 and a light chain of type hukappa, with a predicted molecular weight (MW) of 150 kDa.

Anti-Human/Rat HER2 (neu) Antibody (7.16.4) is a mouse-derived IgG2a, κ monoclonal antibody inhibitor that targets human or rat HER2.

Anti-ERBB1/EGFR/HER1 Antibody is a human-derived antibody expressed in CHO cells, targeting ERBB1/EGFR/HER1. It possesses a human IgG1 heavy chain and a human κ light chain, with an estimated molecular weight (MW) of 145 kDa. For an isotype control, refer to HumanIgG1kappa, Isotype Control.

Anti-ERBB1/EGFR/HER1 Antibody (7A7) is a humanized antibody produced in CHO cells, specifically targeting ERBB1/EGFR/HER1. It features a muIgG1 heavy chain and an mκ light chain, with a predicted molecular weight (MW) of 150 kDa. For isotype control, refer to HumanIgG1kappa, Isotype Control.

Anti-ERBB3/HER3 (SGP1) is a human monoclonal antibody (mAb) targeting ERBB3/HER3. It inhibits Neuregulin-stimulated growth of cultured breast cancer cells and can be utilized in breast cancer research.

Anti-ERBB3/HER3 (29Z6) is an antibody inhibitor targeting human ERBB3/HER3.

Anti-HER3 Antibody (Ab562) is a monoclonal antibody targeting HER3. This specific antibody can be utilized in the synthesis of antibody-drug conjugates (ADC) AMT-562.

Trastuzumab is a humanized monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has been clinically used to treat HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer.